United States· US:67919-030_23d9b7be-abf3-4ca6-bce8-d80643a708e7
ZERBAXA
A medicinal product containing ceftolozane sulfate; tazobactam sodium, registered in United States by Merck Sharp & Dohme LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1167919-030-01
- ndc11679190300110 VIAL, SINGLE-DOSE in 1 CARTON (67919-030-01) / 10 mL in 1 VIAL, SINGLE-DOSE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozane sulfate; tazobactam sodium in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8eee16f-4078-4879-b9ba-494320922419 GET /v1/drugs/a8eee16f-4078-4879-b9ba-494320922419?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "1; .5",
"substance": "CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM",
"productndc": "67919-030",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "g/10mL; g/10mL",
"application_number": "NDA206829",
"marketing_category": "NDA"
}See everything about ceftolozane sulfate; tazobactam sodium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.